India’s apex drug regulator has barred drugmakers from directly or indirectly promoting prescription-only weight-loss drugs, tightening scrutiny just as global and domestic companies gear up to expand their obesity portfolios in the country. The advisory targets not only conventional advertisements but also disease-awareness campaigns, influencer content and corporate branding efforts that, in effect, build visibility and recall for these medicines among the general public.
In a notice issued to manufacturers and importers, Drugs Controller General of India (DCGI) Dr Rajeev Raghuvanshi has warned companies against any form of promotion for these prescription products across print, electronic, digital and social media platforms. The move comes amid an aggressive marketing push by multinational firms following the launch of high-profile GLP-1 receptor agonist brands such as Mounjaro, marketed by Eli Lilly, and Novo Nordisk’s Wegovy and Ozempic in the Indian market.
Regulators have been tracking a surge in indirect promotions around GLP-1 drugs, which are used for diabetes and obesity management and have attracted intense public interest globally. The DCGI advisory specifically flags “surrogate advertisements” and makes clear that activities presented as disease education, wellness campaigns or influencer-led content will not be exempt if they effectively promote a specific prescription drug to lay audiences.
“Any form of advertising or promotional activity, direct or indirect, across print, electronic, digital and social media platforms to promote the product to the general public is prohibited,” the advisory states. It further clarifies that campaigns run “under the pretext of disease awareness, influencer engagement, corporate campaigns or similar activities that create brand recall or product visibility” for prescription-only medicines will be treated as violations.
The regulator has also cautioned against misleading therapeutic claims. According to the advisory, advertisements that exaggerate efficacy, promise guaranteed weight-loss outcomes or downplay the role of diet, exercise and other lifestyle measures in obesity management will attract regulatory action. Obesity is a chronic metabolic condition, the DCGI notes, and where drug therapy is indicated, it must not be projected in a way that undermines public health messages on prevention and lifestyle modification.
Companies have been told to align with ethical marketing standards and ensure that the manufacture, sale, distribution and promotion of drug products strictly adhere to approved indications, conditions of permission, labelling norms and other statutory requirements. Promotional practices deemed irrational or misleading, including so-called awareness campaigns that double up as brand-building exercises, will be taken seriously, the advisory warns.
The timing of the clampdown is significant for the rapidly evolving obesity-treatment market. Following the introduction of GLP-1 based brands by multinational players, local distributors expect a wave of domestic entries once patents expire. According to market estimates quoted by distributors, around 50 brands of semaglutide-based products could enter the Indian market in the initial phase after the expiry of the semaglutide patent on 21 March.
That level of competition typically leads to intense marketing activity, particularly in a therapy area that has already captured public attention via social media and celebrity-driven narratives. By moving early to define what constitutes indirect advertising for prescription-only weight-loss drugs, the DCGI appears to be signalling that commercial strategies must not override safeguards around rational use and public health messaging.
For now, the onus is on pharmaceutical manufacturers, importers and their marketing partners to re-examine ongoing and planned campaigns for obesity and weight-loss drugs in light of the new advisory. How strictly the guidance is enforced, and how companies recalibrate their outreach to healthcare professionals without crossing the line into consumer-facing promotion, will shape the contours of India’s emerging market for next-generation weight-loss therapies.
